

Register of declared interests – SHTG Assessment: Clopidogrel genotype testing after ischaemic stroke or transient ischaemic attack (TIA)

Name		element	interests for the past	Non-personal Financial interests for the past year (12 months)	Personal non-financial interests	Non-personal non- financial interests	Any other interests which could be perceived to affect your impartiality
Mark Barber (Geriatrician/ Stroke Physician, NHS Lanarkshire)	13/11/2023	Peer review	None	None	None	None	None
Jeremy Bridge- Cook (Chief Scientific Officer, Genomadix Inc)	08/07/2024	review	Name of Company/Org: Genomadix Inc Nature of Interest: Shares held by me, salary received by me Date: Ongoing Specific to Topic: Yes Name of Company/Org: Genomadix Inc Nature of Interest: Shares held by my partner Date: Ongoing Specific to Topic: Yes	None	None	None	None

Name	Date of	Projec	Personal Financial	Non-personal Financial	Personal non-financial	Non-personal non-	Any other interests
	declarati	t	interests for the past	interests for the past	interests	financial interests	which could be
	on	eleme	three years	year (12 months)			perceived to affect your
		nt					impartiality

Anthony Byrne (Consultant Physician, NHS Forth Valley)	20/11/2023	review	Name of Company/Org: NHS Forth Valley Nature of Interest: Salary Date: Ongoing Specific to Topic: No	None	None	Name of Company/Org: NHS Forth Valley Nature of Interest: Department involved in clinical research but not involvement in trials with clopidogrel since TARDIS Date: Ongoing Specific to Topic: No	Name of Company/Org: Scottish Intercollegiate Guidelines Network (SIGN) Nature of Interest: Represent RCPE on SIGN Council Date: Ongoing Specific to Topic: No
Alexander Doney (Clinical Reader and Hon NHS Consultant, University of Dundee)	13/11/2023	Peer review	None	None	Name of Company/Org: NICE Diagnostic Advisory Board Nature of Interest: Clopidogrel Phamacogenomics in Stroke Date: Ongoing Specific to Topic: Yes Name of Company/Org: NHS Tayside Pharmocogenomics Initiative Lead Nature of Interest: Pharmacogenomics implementation Date: Ongoing Specific to Topic: Yes Name of Company/Org: National rollout of	Name of Company/Org: University of Dundee Nature of Interest: General Pharmacogenomics and Precision Medicine research and teaching Date: Ongoing Specific to Topic: Yes	None

Name	Date of	Projec	Personal Financial	Non-personal Financial	Personal non-financial	Non-personal non-	Any other interests
	declarati	t	interests for the past	interests for the past	interests	financial interests	which could be
	on	eleme	three years	year (12 months)			perceived to affect your
		nt					impartiality

					Clopidogrel Pharmacogenomics ANIA Nature of Interest: Clopidogrel Pharmacogenomics in Stroke and other use cases Date: Ongoing Specific to Topic: Yes		
Peter Kerr (Advanced Nurse Practitioner in Stroke, NHS Greater Glasgow & Clyde)	20/11/2023	Peer review	None	None	None	None	None
Alexandre Matos (Specialist Clinical Pharmacist, NHS Tayside)	13/11/2023	Peer review	None	None	None	None	None
Zofia Miedzybrodz ka (Professor of Medical Genetics/Serv ice Clinical	06/12/2023	Peer review		Name of Company/Org: Novartis & Roche Nature of Interest: Application for Scottish newborn screening pilot for SMA Date: N/A Specific to Topic: No	Name of Company/Org: Novartis, Roche, Astra Zeneca, Janssen. Nature of Interest: Advisory boards money paid to department Date: Ongoing Specific to Topic: No	None	Name of Company/Org: Attended educational meetings in UK sponsored by MSD, Sanofi, Amgen, Novartis, Roche, AstraZeneca. Nature of Interest: Attended meetings

Name	Date of	Projec	Personal Financial	Non-personal Financial	Personal non-financial	Non-personal non-	Any other interests
	declarati	t	interests for the past	interests for the past	interests	financial interests	which could be
	on	eleme	three years	year (12 months)			perceived to affect your
		nt					impartiality

Director		sponsored by various
Genetics,	Name of Company/Org:	volcanoes
NHS	Akcea and Astra Zeneca	Date: N/A
Grampian/Ch	Nature of Interest:	Specific to Topic: No
air Scottish		specific to ropic. No
Clinical	Payment to department for tests in unrelated area	
		Name of Company/Org:
Genetics	Date: N/A	Novartis
Forum)	Specific to Topic: No	Nature of Interest:
		Attended visit of
	Name of Company/Org:	Norwegian newborn
	Akcea and Astra Zeneca	screening lab organised by
	Nature of Interest: Acted	Novartis
	as expert advisor giving a	Date interest ceased:
	talk about a condition that	February 2023
	there is treatment for	Specific to Topic: No
	Date: N/A	
	Specific to Topic: No	
	Name of Company/Org:	
	Astra zeneca	
	Nature of Interest: Spoke	
	at sponsored meeting on	
	breast cancer. Fee to	
	depart	
	Date: N/A	
	Specific to Topic: No	
	Name of Company/Org:	
	PTC therapeutics	
	Nature of Interest:	
	University paid for my time	

Name	Date of	Projec	Personal Financial	Non-personal Financial	Personal non-financial	Non-personal non-	Any other interests
	declarati	t	interests for the past	interests for the past	interests	financial interests	which could be
	on	eleme	three years	year (12 months)			perceived to affect your
		nt					impartiality

				delivering an educational session Date interest ceased: March 2021 Specific to Topic: No			
Mark Redpath (Consultant Biochemist, NHS Borders)	13/11/2023	Peer review	Nothing declared	Nothing declared	Nothing declared	Nothing declared	Nothing declared
Austin Willett (CEO Different Strokes)	07/12/2023	Peer review	None	None	Name of Company/Org: Different Strokes Nature of Interest: I am CEO of Different Strokes, and we support stroke survivors so have a desire to see the best possible post-stroke support for people Date: Ongoing Specific to Topic: No	Name of Company/Org: Different Strokes Nature of Interest: I am responsible for other staff members of Different Strokes, who from time to time will make public statements supporting stroke survivors Date: Ongoing Specific to Topic: No	None